Please select the option that best describes you:
How do you treat patients with T-cell ALL/T-cell lymphoblastic lymphoma who have pre-existing CKD with a CrCl of 30 mL/min or less?
Many of the agents in either BFM protocols or hyper-CVAD (e.g., methotrexate, cytarabine, 6-mercaptopurine) are renally cleared. How do you deliver the chemotherapy to ensure enough dose intensity but not significant cytopenias/toxicity?
Answer from: Medical Oncologist at Academic Institution
In our experience, it requires very close coordination with our clinical pharmacists to ensure proper dose adjustments are made. Fortunately, there isn't much nephrotoxicity with the agents we use for ALL, so the risk of seeing the CKD worsen is hopefully low. The agents that make me the most nervou...
Sign in or Register to read more